Select your country
Websites worldwide
Select a country to go to the website of the respective STADA sales company.
Australia (1)
Austria (1)
Belarus (1)
Belgium (1)
Bosnia-Herzegovina (1)
Bulgaria (1)
China (1)
Croatia (1)
Czech Republic (2)
Denmark (1)
France (1)
Hungary (1)
Ireland (1)
Italy (1)
Montenegro (1)
Netherlands (2)
Poland (1)
Portugal (1)
Romania (1)
Saudi Arabia (1)
Serbia (1)
Slovakia (1)
Slovenia (1)
Spain (1)
Switzerland (1)
The Phillippines (1)
United Kingdom (3)
Vietnam (2)
![STADA and Calliditas - filing for full marketing authorization for Kinpeygo® in the EU](http://dmle128v1x6xv.cloudfront.net/media/7302/20220920_press_release_stada_kinpeygo_launch_listing_609x571.jpg?anchor=center&mode=crop&width=656&height=457&rnd=133081031840000000)
STADA and Calliditas announce the filing for full marketing authorization for Kinpeygo® in the EU
![STADA: FDA approves biologics facility to supply key medicine to patients in US](http://dmle128v1x6xv.cloudfront.net/media/7656/20230601_pressrelease_norbitec_650x375.jpg?anchor=center&mode=crop&width=656&height=457&rnd=133306051600000000)
Norbitec biotech facility in Uetersen, Germany, a company controlled by STADA, passes inspection by the US FDA
![STADA and Xbrane launch ranibizumab to support patient access in Europe](http://dmle128v1x6xv.cloudfront.net/media/7633/20230403_press-release_stada_ranibizumab_650x375.png?anchor=center&mode=crop&width=656&height=457&rnd=133249940050000000)
Ranibizumab biosimilar is being launched in major European markets
![STADA sustains strong momentum with double-digit sales and profit growth in 2022](http://dmle128v1x6xv.cloudfront.net/media/7584/20230306_press-release_stada_fy2022-results_650x375.jpg?anchor=center&mode=crop&width=656&height=457&rnd=133223571260000000)
Full year 2022 results